Bone Disease Associated with Inactivating Aromatase Mutations and its Management

Area of Science:

• Endocrinology
• Genetics
• Skeletal Biology

Background:

• Aromatase deficiency is a rare autosomal recessive disorder resulting from loss-of-function mutations in the CYP19A1 gene.
• It affects both males and females, with an incidence below 1 in 1,000,000.
• Clinical manifestations differ between sexes, with females often showing signs at birth and males typically diagnosed in late puberty due to skeletal abnormalities.

Purpose of the Study:

• To review current knowledge on the skeletal and extraskeletal phenotype of aromatase deficiency.
• To summarize the clinical management of bone health in patients with CYP19A1 gene mutations.

Main Methods:

• Literature review of published studies on aromatase deficiency.
• Analysis of clinical data regarding skeletal and extraskeletal manifestations.
• Evaluation of current therapeutic strategies for bone health.

Main Results:

• Aromatase deficiency leads to distinct phenotypes in males and females, including variations in sexual development and skeletal maturation.
• Key skeletal findings include tall stature, unfused epiphyses, and reduced bone mass, particularly in males diagnosed later in life.
• Extraskeletal manifestations and long-term bone health require careful monitoring and management.

Conclusions:

• Aromatase deficiency presents with significant skeletal implications, necessitating early diagnosis and intervention.
• Comprehensive management strategies are crucial for addressing both the skeletal and extraskeletal aspects of the disorder.
• Further research is needed to optimize long-term bone health outcomes in affected individuals.